Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction |
Jun 2023 |
SAGE Open Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
Jul 2023 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
Apr 2023 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
Transfusion Support of Patients with Myelodysplastic Syndromes |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes |
Apr 2021 |
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
Jul 2020 |
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. |
Jan 2019 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS) |
May 2024 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |